Related Experiment Video
Updated: Jan 20, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
The gut microbiome and cardiovascular disease: current knowledge and clinical potential
Adilah F Ahmad1,2, Girish Dwivedi1,2,3, Fergal O'Gara4,5,6,7
1Medical School, University of Western Australia, Perth, Western Australia, Australia.
Abstract:
Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is populated by a diverse community of microbes, dominated by bacteria, but also including viruses and fungi. The largest and most complex of these communities is located in the gastrointestinal system and, with its associated genome, is known as the gut microbiome. Gut microbiome perturbations and related dysbiosis have been implicated in the progression and pathogenesis of CVD, including atherosclerosis, hypertension, and heart failure. Although there have been advances in the characterization and analysis of the gut microbiota and associated bacterial metabolites, the exact mechanisms through which they exert their action are not well understood. This review will focus on the role of the gut microbiome and associated functional components in the development and progression of atherosclerosis. Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD are also discussed.
Related Concept Videos
09:09In Silico Clinical Trials for Cardiovascular Disease
09:18A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
08:38Application of Flow Vermimetry for Quantification and Analysis of the Caenorhabditis elegans Gut Microbiome
10:51Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device
07:32A Double Humanized BLT-mice Model Featuring a Stable Human-Like Gut Microbiome and Human Immune System
07:42Quantification of the Potential Impact of Glyphosate-Based Products on Microbiomes

